March 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 7
Nick Curzen
In this issue of Acute and Interventional Cardiology there is a commissioned editorial about the release of cardiac enzymes after percutaneous coronary intervention (PCI). This remains a contentious area and attracts the views of two opposing schools of thought.
January 2004 Br J Cardiol 2004;11:22-3
Jeremy Bray
The management of advanced heart failure when medical treatment alone is no longer sufficient was the focus of the 2003 British Society for Heart Failure (BSH) annual autumn meeting, held in Oxford on 28 November.
January 2004 Br J Cardiol 2004;11:16-21
BJCardio editorial team
A joint British Journal of Cardiology and H.E.A.R.T UK round table meeting held at the National Heart and Lung Institute, 18th November 2003.
January 2004 Br J Cardiol 2004;11:5-7
Mary N Sheppard
It seems ironic that, at a time of ultra-specialisation, when
the public is demanding higher standards from doctors,
academic medicine is being downgraded. Cardiac pathology
represents a perfect case in point.
November 2003 Br J Cardiol 2003;10:428-30
John Greenwood
The introduction of the first specialist registrar training programme in December 1995 brought a radical overhaul in higher specialist training. Each speciality produced a curriculum establishing specific training objectives against which the progress of an individual trainee could be judged.
November 2003 Br J Cardiol 2003;10:426-7
Debbie Hughes
The traditional role of the cardiac nurse, particularly at the inception of the coronary care unit (CCU), has been evolving since the early 60s.
November 2003 Br J Cardiol 2003;10:424-5
J Malcolm Walker
Cardiac rehabilitation has historically been an underdeveloped service in the UK. It is now recognised as an essential component in the management of heart disease and will shortly encompass those at risk of developing cardiovascular disorders.
November 2003 Br J Cardiol 2003;10:421-3
Susan Kennedy
Hypertension is one of the major risk factors for vascular disease and its treatment to target requires not only careful monitoring with lifestyle advice and pharmacological intervention but also a good understanding of the condition by the patient.
November 2003 Br J Cardiol 2003;10:418-20
Neil R Poulter
During the second half of the twentieth century our knowledge of the aetiology of and pathophysiological mechanisms underlying hypertension have advanced immeasurably. Furthermore, few, if any, areas of medicine have as many major morbidity and mortality trials to inform optimal management as does hypertension.
November 2003 Br J Cardiol 2003;10:416-7
Julie Foxton, Anthony Wierzbicki, John Reckless
The merits of reducing cholesterol to help prevent coronary heart disease (CHD) were questioned 10 years ago. There were great debates about the utility of reducing low-density lipoprotein cholesterol (LDL-C) and it is now clear, following the publication of at least eight different clinical drug trials, that reducing cholesterol with statin drugs helps to reduce total mortality, cardiovascular mortality and morbidity and interventional procedures.
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits